What the public record says
The TGA regulates advertising of therapeutic goods in Australia and explains that some goods, including prescription medicines and other restricted goods, cannot be advertised to the public. For peptide buyers, the practical check is whether a page turns research, wellness, recovery, fat-loss, injury, hormone, or anti-ageing language into a therapeutic outcome claim before the evidence and lawful pathway are visible.
What buyers should check
- Do not treat research-use-only wording as a free pass if the same page makes treatment, healing, weight-loss, hormone, anti-ageing, or injury-recovery claims.
- Check whether testimonials, before-after content, and influencer codes are being used to imply outcomes that the seller cannot advertise directly.
- If a product is prescription-only or otherwise restricted, public advertising can be a compliance problem even when checkout still works.
- Advertising-risk findings should be tied to the exact page, screenshot date, claim language, and source URL.
- Peptide Checker should not say a vendor breached the law without a regulator or court source. It can still say the claim needs advertising-risk review.
- Every vendor page should separate product proof, legal pathway proof, and advertising-risk proof instead of collapsing them into one trust score.
Source links
- TGA advertising basics for therapeutic goods
- TGA what can and cannot be advertised
- TGA unapproved peptide products safety advisory
Use this regulatory brief to ask better supplier questions. Do not convert a market-level warning into a vendor-specific claim unless the vendor page has a source attached.
Open vendor scorecards